X

Trial Profile

A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Relapased or Refractory Chronic Lymphocytic Leukemia

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 15 Jun 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Navitoclax (Primary)
Indications Chronic lymphocytic leukaemia
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Sponsors Abbott GmbH & Co. KG; AbbVie; AbbVie Germany

Most Recent Events

08 Jul 2022 Status changed from active, no longer recruiting to completed.
19 Feb 2020 Planned End Date changed from 4 Sep 2020 to 8 Jul 2022.
19 Feb 2020 Planned primary completion date changed from 31 Aug 2018 to 8 Jul 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com